Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced the pricing of its upsized underwritten public offering of 6,000,000 common ...

SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the Oppenheimer Movers in Rare Disease Summit being ...

New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF ...

Zymeworks’ management will participate in one-on-one meetings and a corporate presentation on January 14, 2026, at 3:00 pm PT. About Zymeworks Inc.

Les adolescents et les jeunes adultes (AJA) atteints de cancer ont des besoins spécifiques par rapport aux autres groupes ...

Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the ...

Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (along with its subsidiaries, “Verano” or the “Company”), a leading multi-state cannabis company, today announced the Texas Department of Public ...

Mont-Saint-Guibert (Belgique), le 2 décembre 2025, 22:30h CET / 16:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nyxoah SA ...

The webcast can be accessed under “Events and Presentations” on the Investors section of the Black Diamond website at www.blackdiamondtherapeutics.com. A replay of the webcast will be available ...

QTX-2101 is an investigational, oral arsenic trioxide therapy that has not yet been approved by any regulatory authority. Its safety and efficacy are currently under evaluation. This press release ...

Specifically, between 19 November and 28 November 2025, Mr. Siokas executed five transactions, acquiring 301,101 shares. So far in 2025, he has added 3,398,055 shares to his holdings. Following these ...

To support the rapid progression of this pipeline, LAMY will expand its executive leadership and Board of Directors, with plans to announce a Chief Science Officer and Chief Medical Officer, and form ...